Table 1.
Baseline characteristics of all enrolled patients
| Characteristics | n (%) or mean±SD |
| Age (years) | 58.6±10.1 |
| Gender | |
| Male | 22 (95.7) |
| Female | 1 (4.3) |
| Smoking status | |
| Never | 7 (30.4) |
| Former or current | 16 (69.6) |
| Alcohol consumption | |
| Never | 11 (47.8) |
| Former or current | 12 (52.2) |
| Tumor location | |
| Upper segment | 1 (4.3) |
| Middle segment | 9 (39.1) |
| Lower segment | 13 (56.5) |
| Clinical TNM stage* | |
| II | 8 (34.8) |
| III | 15 (65.2) |
| Performance score | |
| 0 | 21 (91.3) |
| 1 | 2 (8.7) |
| PD-L1, CPS | |
| <1 | 7 (30.4) |
| ≥1 | 12 (52.2) |
| NE | 4 (17.4) |
| TMB status | |
| TMB-H (≥7 Muts/Mb) | 5 (21.7) |
| TMB-L (<7 Muts/Mb) | 14 (60.9) |
| NE | 4 (17.4) |
*Clinical disease stage was assessed according to the criteria of the American Joint Committee on Cancer, Eighth Edition.
CPS, combined positive score; NE, not evaluable; PD-L1, programmed death-ligand 1; TMB, tumor mutation burden; TMB-H, tumor mutation burden-high; TMB-L, tumor mutation burden-low; TNM, tumor node metastasis.